TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.0570nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.0590nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.0600nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.0630nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.0670nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.0720nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.0920nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.120nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.130nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.140nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.160nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.490nMAssay Description:Inhibition of N-terminal FLAG-tagged EZH2 in PRC2 complex (unknown origin) expressed in baculovirus infected Sf9 cells using H2N-RKQLATKAAR(Kme0)SAPA...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals
Curated by ChEMBL
Constellation Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair